ABSTRACT
BACKGROUND: DNA topoisomerase (Topo) inhibition plays key role in breast cancer treatment. Stephania hainanensis H. S. Lo et Y. Tsoong (S. hainanensis), a Li nationality plant that has abundant aporphine alkaloids, can inhibit Topo. PURPOSE: To identify a dual Topo inhibitor, a deep and systematic study of active aporphine alkaloids in S. hainanensis and their mechanisms of inhibiting breast cancer proliferation and Topo activity are essential. STUDY DESIGN: This study aimed to assess the anti-breast cancer and Topo inhibitory activities of oxocrebanine and explore the underlying mechanisms. METHODS: The growth inhibitory activities of 12 compounds in S. hainanensis were screened by MTT assay in MCF-7, SGC-7901, HepG-2 cells, and compared with the effects on human normal mammary epithelial MCF-10A cells as non cancer control cells. The Topo inhibitory activity was assessed by DNA relaxation and unwinding assays, kDNA decatenation assay and western blot. Cell cycle and autophagy analyses were carried out with flow cytometry and staining. Acridine orange staining and α-tubulin morphology were observed by fluorescence microscopy. Western blot was used to examine microtubule assembly dynamics and the expression levels of key proteins associated with DNA damage, autophagy and mitotic arrest. RESULTS: Oxocrebanine was the anti-breast cancer active alkaloid in S. hainanensis. It exhibited the best inhibitory effect on MCF-7 cells with an IC50 of 16.66 µmol/l, and had only weak effect on the proliferation of MCF-10A cells. Oxocrebanine inhibited Topo I and II α in a cell-free system and in MCF-7 cells. The DNA unwinding assay suggested that oxocrebanine intercalated with DNA as a catalytic inhibitor. Oxocrebanine regulated the levels of Topo I and IIα and DNA damage-related proteins. Oxocrebanine led to the mitotic arrest, and these effects occurred through both p53-dependent and p53-independent pathways. Oxocrebanine induced autophagy, abnormal α-tubulin morphology and stimulated enhanced microtubule dynamics. CONCLUSION: Oxocrebanine was the anti-breast cancer active aporphine alkaloid in S. hainanensis. Oxocrebanine was a Topo I/IIα dual inhibitor, catalytic inhibitor and DNA intercalator. Oxocrebanine caused DNA damage, autophagy, and mitotic arrest in MCF-7 cells. Oxocrebanine also disrupted tubulin polymerization. Accordingly, oxocrebanine held a great potential for development as a novel dual Topo inhibitor for effective breast cancer treatment.
Subject(s)
Antineoplastic Agents, Phytogenic/therapeutic use , Aporphines/therapeutic use , Breast Neoplasms/drug therapy , Topoisomerase Inhibitors/therapeutic use , Alkaloids/pharmacology , Antineoplastic Agents, Phytogenic/chemistry , Antineoplastic Agents, Phytogenic/pharmacology , Aporphines/chemistry , Aporphines/pharmacology , Breast Neoplasms/pathology , Cell Cycle/drug effects , Cell Line, Tumor , Cell Proliferation/drug effects , DNA Damage , DNA Topoisomerases, Type I/metabolism , DNA Topoisomerases, Type II/metabolism , Drug Screening Assays, Antitumor , Female , Humans , MCF-7 Cells , Mitosis/drug effects , Topoisomerase Inhibitors/chemistry , Topoisomerase Inhibitors/pharmacologyABSTRACT
BACKGROUND AND OBJECTIVE: Drug resistance and adverse effects are immense healthcare challenges in cancer therapy. Benzimidazole ring-based small molecules have been effective anticancer agents in drug development. In an effort to develop novel chemotherapeutics, we synthesized and assessed the anticancer and antibacterial activities of a small library of structurally unique benzimidazoles. METHODS: The benzimidazoles were derived from indole, N-alkyl indole, fatty acid, and alpha-amino acid scaffolds providing a panel of diverse structures. The compounds were tested in three different cancer cell lines for cytotoxicity: HepG2 (human hepatocellular carcinoma), HeLa (human cervical carcinoma), and A549 (human lung carcinoma). Mechanism of cell death induced by benzimidazoles was evaluated using fluorescent dye-based apoptosis-necrosis assay, immunoblotting for active caspases, topoisomerase-II activity assay, and cell cycle assay. RESULTS: Cell viability testing revealed that indole- and fatty acid-based benzimidazoles were most potent followed by the amino acid derivatives. Many compounds induced cytotoxicity in a concentration-dependent manner with cellular cytotoxicity (CC50) <20µM in the cell lines tested. Most compounds exhibited cytotoxicity via apoptosis through the intrinsic pathway. Inhibition of topoisomerase activity and cell cycle alterations were not the primary mechanisms of cytotoxicity. In addition, several compounds showed promising activity against S. aureus and S. epidermidis (Minimum Inhibitory Concentration (MIC) of as low as 0.04µmol/mL). CONCLUSION: The reported benzimidazole derivatives possess promising anticancer and antibacterial properties. Additionally, we discovered apoptosis to be the primary mechanism for cancer cell death induced by the tested benzimidazoles. Our findings suggest that further development of these scaffolds could provide drug leads towards new chemotherapeutics.
Subject(s)
Anti-Bacterial Agents/chemical synthesis , Antineoplastic Agents/chemical synthesis , Benzimidazoles/chemical synthesis , A549 Cells , Amino Acids/chemistry , Anti-Bacterial Agents/pharmacology , Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Benzimidazoles/pharmacology , DNA Topoisomerases/metabolism , Drug Evaluation, Preclinical , Escherichia coli/drug effects , Fatty Acids/chemistry , HeLa Cells , Hep G2 Cells , Humans , Indoles/chemistry , Microbial Sensitivity Tests , Staphylococcus aureus/drug effects , Staphylococcus epidermidis/drug effects , Structure-Activity Relationship , Topoisomerase Inhibitors/chemical synthesis , Topoisomerase Inhibitors/pharmacologyABSTRACT
Bioassay-guided fractionation of an ethanolic extract of Ochrosia borbonica led to the isolation of two known pyridocarbazole alkaloids, ellipticine (1) and 9-methoxyellipticine (2), and six known monoterpenoid indole alkaloids (3-8). Lipid-lowering assay in 3T3-L1 cell model revealed that 1 and 2 could significantly inhibit the lipid droplet formation (EC50 = 0.41 and 0.92 µmol·L-1, respectively) and lower triglyceride levels by 50%-60% at the concentration of 1 µmol·L-1, being more potent than the positive drug luteolin (EC50 = 2.63 µmol·L-1). A mechanistic study indicated that 1 and 2 could intercalate into supercoiled DNA, which consequently inhibited the mitotic clonal expansion of 3T3-L1 cells at the early differentiation phase, leading to the retardance of following adipogenesis and lipogenesis. These findings suggest that 1 and 2 may serve as promising leads for further development of anti-obesity drugs.
Subject(s)
Adipogenesis/drug effects , Carbazoles/pharmacology , Cell Proliferation/drug effects , DNA, Superhelical/chemistry , Hypolipidemic Agents/pharmacology , Ochrosia/chemistry , 3T3-L1 Cells , Adipocytes/drug effects , Adipocytes/metabolism , Adipocytes/pathology , Animals , Carbazoles/chemistry , Carbazoles/metabolism , DNA Damage , Ellipticines/chemistry , Ellipticines/metabolism , Ellipticines/pharmacology , Hypolipidemic Agents/chemistry , Hypolipidemic Agents/metabolism , Lipid Metabolism/drug effects , Mice , Molecular Structure , Plant Extracts/chemistry , Topoisomerase Inhibitors/chemistry , Topoisomerase Inhibitors/metabolism , Topoisomerase Inhibitors/pharmacologyABSTRACT
A novel anthraquinone, 2-(dimethoxymethyl)-1-hydroxyanthracene-9,10-dione (1), together with nine known compounds (2-10), were isolated from the fermentation of Aspergillus versicolor derived from deep sea sediment. Their structures were established through spectroscopic methods. Compound 1 exhibited strong inhibitory activities against MRSA ATCC 43300 and MRSA CGMCC 1.12409 (with MIC values of 3.9 and 7.8 µg/mL respectively) and moderate activities against tested strains of Vibrio (with MIC values ranging from 15.6 to 62.5 µg/mL). Compound 1 was subjected to molecular docking studies for inhibition of topoisomerase IV and AmpC ß-lactamase enzymes indicating its usefulness as antimicrobial agent.
Subject(s)
Anthraquinones/chemistry , Anti-Infective Agents/chemistry , Anti-Infective Agents/pharmacology , Aspergillus/chemistry , Aquatic Organisms , Bacterial Proteins/antagonists & inhibitors , Bacterial Proteins/metabolism , DNA Topoisomerase IV/antagonists & inhibitors , Drug Evaluation, Preclinical , Fermentation , Geologic Sediments/microbiology , Methicillin-Resistant Staphylococcus aureus/drug effects , Microbial Sensitivity Tests , Molecular Docking Simulation , Molecular Structure , Topoisomerase Inhibitors/chemistry , Topoisomerase Inhibitors/pharmacology , Vibrio/drug effects , beta-Lactamases/metabolismABSTRACT
Three new compounds, a sesquilignan (1) and two glucosylated phenylpropanoids (2, 3), and seven known compounds (4-10), were isolated from the fruits of Illicium verum HOOK. FIL. (Illiciaceae). The structures of 1-3 were determined based on one and two dimensional (1D- and 2D-) NMR data and electronic circular dichroism (ECD) spectra analyses. Compounds 3, 5, 6, and 8-10 exhibited potent inhibitory activities against topoisomerase II with IC50 values of 54.6, 25.5, 17.9, 12.1, 0.3 and 1.0 µM, respectively, compared to etoposide, the positive control, with an IC50 of 43.8 µM.
Subject(s)
Alkanes/chemistry , DNA Topoisomerases/metabolism , Fruit/chemistry , Illicium/chemistry , Plant Extracts/pharmacology , Alkanes/metabolism , Alkanes/toxicity , Cell Line, Tumor , Cell Survival/drug effects , Circular Dichroism , DNA Topoisomerases/chemistry , Fruit/metabolism , Glucosides/chemistry , Glucosides/metabolism , Glucosides/pharmacology , Humans , Illicium/metabolism , Inhibitory Concentration 50 , Magnetic Resonance Spectroscopy , Molecular Conformation , Phenylpropionates/chemistry , Phenylpropionates/metabolism , Phenylpropionates/pharmacology , Plant Extracts/chemistry , Topoisomerase Inhibitors/chemistry , Topoisomerase Inhibitors/metabolism , Topoisomerase Inhibitors/pharmacologyABSTRACT
Natural products have been used for medical applications since ancient times. Commonly, natural products are structurally complex chemical compounds that efficiently interact with their biological targets, making them useful drug candidates in cancer therapy. Here, we used cell-based phenotypic profiling and image-based high-content screening to study the mode of action and potential cellular targets of plants historically used in Saudi Arabia's traditional medicine. We compared the cytological profiles of fractions taken from Juniperus phoenicea (Arar), Anastatica hierochuntica (Kaff Maryam), and Citrullus colocynthis (Hanzal) with a set of reference compounds with established modes of action. Cluster analyses of the cytological profiles of the tested compounds suggested that these plants contain possible topoisomerase inhibitors that could be effective in cancer treatment. Using histone H2AX phosphorylation as a marker for DNA damage, we discovered that some of the compounds induced double-strand DNA breaks. Furthermore, chemical analysis of the active fraction isolated from Juniperus phoenicea revealed possible anti-cancer compounds. Our results demonstrate the usefulness of cell-based phenotypic screening of natural products to reveal their biological activities.
Subject(s)
Antineoplastic Agents/pharmacology , High-Throughput Screening Assays/methods , Plant Preparations/pharmacology , Topoisomerase Inhibitors/pharmacology , Antineoplastic Agents/chemistry , Apoptosis/drug effects , Brassicaceae/chemistry , Caspase 9/metabolism , Cell Survival/drug effects , Citrullus colocynthis/chemistry , DNA Breaks, Double-Stranded/drug effects , DNA Damage , HeLa Cells , Histones/metabolism , Humans , Juniperus/chemistry , Magnetic Resonance Spectroscopy , Mass Spectrometry/methods , Molecular Structure , Phosphorylation/drug effects , Plant Preparations/chemistry , Saudi Arabia , Topoisomerase Inhibitors/chemistry , Tumor Suppressor Protein p53/metabolismABSTRACT
BACKGROUND: Eight plant species from Oaxaca, some of them used in traditional medicine, were subjected to screening of several biological activities to provide data regarding their anticancer potential, although no scientific information is available about their pharmacological effects. MATERIALS AND METHODS: Methanol extracts from stems or roots of the eight plants were tested for antioxidant activity by the DPPH- method. Antimicrobial activity was determined using the agar diffusion method and the minimal inhibitory concentration (MIC) was obtained by broth dilution method. Antitopoisomerase activity was assessed using mutant strains of Saccharomyces cerevisiae JN362a, JN394, JN394t-1, JN394t2.4 and JN394t2-5. The mutagenic activity was evaluated using the Ames test (Salmonella typhimurium TA1535). RESULTS: No extract showed significant antioxidant activity. The best antimicrobial activity was observed for Salpianthus arenarius (MIC 56.25 µg/mL) and Lantana achyranthifolia (MIC 78.12 µg/mL) against Staphylococcus aureus. Extracts of Acalypha cuspidata, Alloispermum integrifolium and L. achyranthifolia stems showed antitopoisomerase II activity with JN394t-1 growth of -30.88±0.0%, -38.11±4.95%, and -70.97±12.02% respectively. Galium mexicanum stem extract showed antitopoisomerase I activity with growth of 35.31±6.36% on the same mutant strain. All plant extracts were non-mutagenic. Fractionation of A. cuspidata extract led to identification of two subfractions with antitopoisomerase I and II activity at 154µg/mL (Positive controls 50 and 100µg/mL). CONCLUSION: Methanol extracts of A. cuspidata, A. integrifolium, G. mexicanum, and L. achyranthifolia stems showed antitopoisomerase and non-mutagenic activities, and consequently could be promising as a source of anticancer drugs.
Subject(s)
Antineoplastic Agents, Phytogenic/pharmacology , Plant Extracts/pharmacology , Plant Roots/chemistry , Plant Stems/chemistry , Anti-Infective Agents/pharmacology , Antioxidants/pharmacology , Methanol/pharmacology , Mexico , Microbial Sensitivity Tests , Mutagenesis/drug effects , Topoisomerase Inhibitors/pharmacologyABSTRACT
INTRODUCTION: Acute myeloid leukemia (AML) represents a disease with a very poor outcome and remains an area of significant unmet need necessitating novel therapeutic strategies. Among novel therapeutic agents, vosaroxin is a first-in-class anticancer quinolone derivative that targets topoisomerase II and induces site-selective double-strand breaks in DNA, leading to tumor cell apoptosis. Areas covered: Herein, the authors provide a comprehensive review of the preclinical development of vosaroxin. This includes coverage of vosaroxin's mechanism of action in addition to its pharmacology and of the main studies reported over the past few years with vosaroxin when used to treat adult AML. Expert opinion: Given that vosaroxin is associated with fewer potential side effects, it may be of benefit to elderly patients with relapsed/refractory AML and to those with additional comorbidities who have previously received an anthracycline and cytarabine combination. Furthermore, vosaroxin also was seen to be active in multidrug-resistant preclinical models. However, further studies have to be performed to better evaluate its place in the armamentarium against AML.
Subject(s)
Antineoplastic Agents/therapeutic use , Leukemia, Myeloid, Acute/drug therapy , Naphthyridines/therapeutic use , Thiazoles/therapeutic use , Adult , Aged , Animals , Antineoplastic Agents/adverse effects , Antineoplastic Agents/pharmacology , Apoptosis/drug effects , DNA Breaks, Double-Stranded/drug effects , Drug Evaluation, Preclinical/methods , Drug Resistance, Multiple , Drug Resistance, Neoplasm , Humans , Leukemia, Myeloid, Acute/pathology , Naphthyridines/adverse effects , Naphthyridines/pharmacology , Thiazoles/adverse effects , Thiazoles/pharmacology , Topoisomerase Inhibitors/adverse effects , Topoisomerase Inhibitors/pharmacology , Topoisomerase Inhibitors/therapeutic useABSTRACT
In the present study, 300 plant derived secondary metabolites (100 each of alkaloid, flavonoid, and terpenoid), have been screened for their anti-cancerous activity through inhibition of selected key enzymatic targets, namely cyclooxygenases (COXs), topoisomerases (Topos), and aromatase by molecular docking approach. Furthermore, the stability of the complexes of top hits, from each class of secondary metabolites, with their respective enzymatic targets was analyzed using molecular dynamics (MD) simulation analyses and binding free energy calculations. Analysis of the results of the docking in light of the pharmacokinetically screened 18 alkaloids, 26 flavonoids, and 9 terpenoids, revealed that the flavonoid, curcumin, was the most potent inhibitor for all the selected enzymatic targets. The stability of the complexes of COX-1, COX-2, Topo I, Topo IIß and aromatase with the most potent inhibitor curcumin and those of the respective drugs, namely ibuprofen, aspirin, topotecan, etoposide, and exemestane were also analyzed through MD simulation analyses which revealed better stability of curcumin complexes than those of respective drugs. Binding energy calculations of the complexes of the curcumin with all the targets, except those of Topos, exhibited lower binding energies for the curcumin complexes than those of respective drugs which corroborated with the results of molecular docking analyses. Thus, the present study affirms the versatile and multipronged nature of curcumin, the traditionally used herbal medicine, as anti-cancer molecule directed against these enzymatic targets.
Subject(s)
Antineoplastic Agents, Phytogenic/chemistry , Aromatase Inhibitors/chemistry , Cyclooxygenase Inhibitors/chemistry , Molecular Docking Simulation , Molecular Dynamics Simulation , Plant Extracts/chemistry , Plants/chemistry , Topoisomerase Inhibitors/chemistry , Antineoplastic Agents, Phytogenic/pharmacology , Aromatase/chemistry , Aromatase/pharmacology , Aromatase Inhibitors/pharmacology , Cyclooxygenase Inhibitors/pharmacology , Flavonoids/chemistry , Flavonoids/pharmacology , Plant Extracts/pharmacology , Plants/metabolism , Protein Binding , Topoisomerase Inhibitors/pharmacologyABSTRACT
Cinnamomum verum is used to make the spice cinnamon and has been used as a traditional Chinese herbal medicine. We evaluated the anticancer effect of 2-methoxycinnamaldehyde (2-MCA), a constituent of the bark of the plant, and its underlying molecular biomarkers associated with carcinogenesis in human lung adenocarcinoma A549 cells. The results show that 2-MCA suppressed proliferation and induced apoptosis as indicated by an upregulation of pro-apoptotic Bax and Bak genes and downregulation of anti-apoptotic Bcl-2 and Bcl-XL genes, mitochondrial membrane potential loss, cytochrome c release, activation of caspase-3 and -9, and morphological characteristics of apoptosis, including plasma membrane blebbing and long comet tail. In addition, 2-MCA also induced lysosomal vacuolation with increased volume of acidic compartment (VAC) and suppressions of nuclear transcription factors nuclear factor-κB (NF-κB) and both topoisomerase I and II activities. Further study reveals that the growth-inhibitory effect of 2-MCA was also evident in a nude mice model. Taken together, the data suggest that the growth-inhibitory effect of 2-MCA against A549 cells is accompanied by downregulations of NF-κB binding activity and proliferative control involving apoptosis and both topoisomerase I and II activities, together with an upregulation of lysosomal vacuolation and VAC. Our data suggest that 2-MCA could be a potential agent for anticancer therapy.
Subject(s)
Acrolein/analogs & derivatives , Antineoplastic Agents, Phytogenic/pharmacology , Cinnamomum zeylanicum/chemistry , Topoisomerase Inhibitors/pharmacology , Acrolein/pharmacology , Adenocarcinoma/drug therapy , Adenocarcinoma of Lung , Animals , Apoptosis/drug effects , Apoptosis Regulatory Proteins/metabolism , Cell Line, Tumor/drug effects , Cytochromes c/metabolism , DNA Topoisomerases, Type I/metabolism , DNA Topoisomerases, Type II/metabolism , Humans , Lung Neoplasms/drug therapy , Male , Membrane Potential, Mitochondrial/drug effects , Mice , Mice, Nude , NF-kappa B/metabolism , Xenograft Model Antitumor AssaysABSTRACT
Oxabicyclooctane linked 1,5-naphthyridinyl-pyridoxazinones are novel broad-spectrum bacterial topoisomerase inhibitors (NBTIs) targeting bacterial DNA gyrase and topoisomerase IV at a site different than quinolones. Due to lack of cross-resistance to known antibiotics they present excellent opportunity to combat drug-resistant bacteria. A structure activity relationship of the pyridoxazinone moiety is described in this Letter. Chemical synthesis and activities of NBTIs with substitutions at C-3, C-4 and C-7 of the pyridoxazinone moiety with halogens, alkyl groups and methoxy group has been described. In addition, substitutions of the linker NH proton and its transformation into amide analogs of AM-8085 and AM-8191 have been reported. Fluoro, chloro, and methyl groups at C-3 of the pyridoxazinone moiety retained the potency and spectrum. In addition, a C-3 fluoro analog showed 4-fold better oral efficacy (ED50 3.9 mg/kg) as compared to the parent AM-8085 in a murine bacteremia model of infection of Staphylococcus aureus. Even modest polarity (e.g., methoxy) is not tolerated at C-3 of the pyridoxazinone unit. The basicity and NH group of the linker is important for the activity when CH2 is at the linker position-8. However, amides (with linker position-8 ketone) with a position-7 NH or N-methyl group retained potency and spectrum suggesting that neither basicity nor hydrogen-donor properties of the linker amide NH is essential for the activity. This would suggest likely an altered binding mode of the linker position-7,8 amide containing compounds. The amides showed highly improved hERG (functional IC50 >30 µM) profile.
Subject(s)
Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacology , Cyclooctanes/chemistry , Drug Evaluation, Preclinical/methods , Structure-Activity Relationship , Topoisomerase Inhibitors/chemistry , Administration, Oral , Animals , Anti-Bacterial Agents/administration & dosage , Chemistry Techniques, Synthetic , DNA Topoisomerase IV/antagonists & inhibitors , ERG1 Potassium Channel , Ether-A-Go-Go Potassium Channels/metabolism , Heterocyclic Compounds, 2-Ring/chemistry , Heterocyclic Compounds, 2-Ring/pharmacology , Mice , Microbial Sensitivity Tests , Naphthyridines/chemistry , Naphthyridines/pharmacology , Staphylococcal Infections/drug therapy , Staphylococcus aureus/drug effects , Staphylococcus aureus/pathogenicity , Topoisomerase Inhibitors/pharmacologyABSTRACT
Complexes of yttrium(III) and dysprosium(III) with the traditional Chinese medicine active ingredient oxoglaucine (OG), namely [Y(OG)2(NO3)3]·CH3OH (1) and [Dy(OG)2(NO3)3]·H2O (2), were synthesized and characterized by elemental analysis, IR, ESI-MS, (1)H and (13)C NMR as well as single-crystal X-ray diffraction analysis. In vitro the complexes exhibited higher anticancer activity than the free ligand OG against the tested cancer cell lines. Among the tested cell lines, HepG2 is the most sensitive to the complexes. Complex 2 can trigger DNA damage in HepG2 cells, resulting in cell cycle arrest in the S phase and leading to cell apoptosis. The S phase cell-cycle arrest is caused via the ATM (ataxia-telangiectasia mutated)-Chk2-Cdc25A pathway. Chk2 is phosphorylated and activated in an ATM-dependent manner. It, in turn, phosphorylates Cdc25A phosphatise on serine124, causing the inactivation of Cdc25A in ubiquitin-mediated proteolytic degradation. The cyclin-Cdk complexes of the S phase could also be inhibited by limited supply of cyclins A and E. This irreversible cell cycle arrest process ultimately induces mitochondria-involved apoptotic cell death via the activation of Bcl-2 protein. Complex e2 ffectively inhibited tumour growth in the BEL-7402 xenograft mouse model and exhibited higher safety in vivo than cisplatin.
Subject(s)
Antineoplastic Agents , Apomorphine/analogs & derivatives , Coordination Complexes , Dysprosium , Topoisomerase Inhibitors , Yttrium , Animals , Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Apomorphine/chemistry , Apomorphine/pharmacology , Apomorphine/therapeutic use , Apoptosis/drug effects , Cell Cycle Checkpoints/drug effects , Cell Line , Cell Line, Tumor , Cell Survival/drug effects , Coordination Complexes/chemistry , Coordination Complexes/pharmacology , Coordination Complexes/therapeutic use , DNA/metabolism , DNA Damage , Dysprosium/chemistry , Dysprosium/pharmacology , Dysprosium/therapeutic use , Humans , Medicine, Chinese Traditional , Mice , Neoplasms/drug therapy , Neoplasms/pathology , Proto-Oncogene Proteins c-bcl-2/metabolism , S Phase/drug effects , Solubility , Topoisomerase Inhibitors/chemistry , Topoisomerase Inhibitors/pharmacology , Topoisomerase Inhibitors/therapeutic use , Tumor Burden/drug effects , Water/chemistry , X-Ray Diffraction , Yttrium/chemistry , Yttrium/pharmacology , Yttrium/therapeutic useABSTRACT
Fraxetin is one of the main constituents of the traditional medicinal plant Fraxinus rhynchophylla. The inhibitory effect of fraxetin on various bacterial strains has been extensively reported, however, its mechanism of action on bacterial cells remains to be elucidated. In the present study, the antibacterial mechanism of fraxetin on Staphylococcus aureus was systematically investigated by examining its effect on cell membranes, protein synthesis, nucleic acid content and topoisomerase activity. The results indicated that fraxetin increased the permeability of the cell membrane but did not render it permeable to macromolecules, such as DNA and RNA. Additionally, the quantity of protein, DNA and RNA decreased to 55.74, 33.86 and 48.96%, respectively following treatment with fraxetin for 16 h. The activity of topoisomerase I and topoisomerase II were also markedly inhibited as fraxetin concentration increased. The result of the ultravioletvisible spectrophotometry demonstrated that the DNA characteristics exhibited a blue shift and hypochromic effect following treatment with fraxetin. These results indicated that fraxetin had a marked inhibitory effect on S.aureus proliferation. Further mechanistic studies showed that fraxetin could disrupt nucleic acid and protein synthesis by preventing topoisomerase from binding to DNA.
Subject(s)
Anti-Bacterial Agents/pharmacology , Coumarins/pharmacology , Protein Synthesis Inhibitors/pharmacology , Staphylococcus aureus/drug effects , Bacterial Proteins/biosynthesis , Cell Membrane/drug effects , DNA Replication/drug effects , DNA Restriction Enzymes/antagonists & inhibitors , DNA Restriction Enzymes/metabolism , DNA Topoisomerases/metabolism , DNA, Bacterial/biosynthesis , Microbial Viability/drug effects , Protein Binding , Protein Biosynthesis/drug effects , Restriction Mapping , Staphylococcus aureus/metabolism , Topoisomerase Inhibitors/pharmacologyABSTRACT
Due to the increasing prevalence of antibiotic resistance and the yet low output of the genomics-based drug discovery approach novel strategies are urgently needed to detect new antibiotics. One such strategy uses known ubiquitous targets like DNA topoisomerases. However, to detect inhibitors of these enzymes by an in vitro assay time-consuming isolation of enzymes and DNA followed by electrophoretic separation of topoisomers are required. Instead, this study aimed at developing an in vivo assay for the detection of alterations in DNA supercoiling indicative of topoisomerase inhibition by a reporter gene assay. A pair of plasmids was developed which carry the reporter gene luc for firefly luciferase under control of either promoter ptopA (pPHB90) or pgyrA (pPHB91), whose activities are reciprocally affected by alterations of the supercoiling degree. Each plasmid is individually transferred into E. coli cells. The quotient of the luciferase activities determined using cells with either plasmid was taken as relative measure of the global supercoiling degree Qsc (quotient of supercoiling). Using isogenic reference strains with known alterations of the global DNA supercoiling degree due to mutations in either gyrB or topA, the reporter gene system was able to detect both a decrease and an increase of the negative supercoiling degree compared to the isogenic parent strain. Treating cells with known inhibitors of DNA gyrase, like fluoroquinolones, novobiocin as well as simocyclinone D8 from Streptomyces antibioticus which has been identified as an inhibitor of DNA gyrase in vitro, also caused decreases of the Qsc value in vivo. The suitability of this reporter gene system to screen for anti-topoisomerase I and II compounds from various natural sources like plant extracts by sensing alterations of the DNA supercoiling was demonstrated and offers a new application to identify novel compounds active against bacterial topoisomerases I and gyrase.
Subject(s)
DNA, Bacterial/analysis , DNA, Superhelical/analysis , Angelica/chemistry , Animals , Bacteria/chemistry , Coumarins/chemistry , Coumarins/pharmacology , DNA Gyrase/genetics , DNA Topoisomerases, Type I/genetics , Enzyme Inhibitors/pharmacology , Escherichia coli/chemistry , Ethidium/chemistry , Fireflies/chemistry , Fireflies/genetics , Genes, Reporter , Glycosides/chemistry , Glycosides/pharmacology , Methoxsalen/pharmacology , Mutation/genetics , Photosensitizing Agents/pharmacology , Ruta/chemistry , Topoisomerase II Inhibitors , Topoisomerase Inhibitors/pharmacology , Umbelliferones/pharmacologyABSTRACT
Low molecular weight (LMW) polyphenolics containing a polyhydroxylated benzyl moiety are abundant in medicinal plants. In the present study, we report on the activities of seven LMW polyphenolics isolated from Inonotus obliquus, a medicinal mushroom. The isolated compounds included caffeic acid (CA), 3,4-dihydroxybenzalacetone (DBL), gallic acid, syringic acid, protocatechuic acid, 3,4-dihydroxybenzaldehyde and 2,5-dihydroxyterephthalic acid. We analyzed their inhibitory effects on DNA polymerase (pol) and DNA topoisomerase (topo), and their effects on human cancer cell growth. All isolated compounds inhibited human topo II activity; the most potent were DBL and CA, which contain a catechol propanoid moiety. CA and DBL inhibited the activity of human topo I, whereas other compounds had no effect. No compound modulated the activities of 11 mammalian pol species or other DNA metabolic enzymes, including T7 RNA polymerase, mouse IMP dehydrogenase (type II), T4 polynucleotide kinase and bovine deoxyribonuclease I. CA and DBL markedly suppressed the proliferation of human colon HCT116 carcinoma cells with an LD50 of 70.0 and 49.4 µM, respectively, and halted the cell cycle in the G2/M phase. The suppressive effect of these compounds on cancer cell growth correlated with their ability to inhibit topo II. These results suggest that CA- and DBL-dependent decreases in cell proliferation are due to the inhibition of cellular topo II. The mechanism of action of these catechol propanoid compounds and the implication for their use as anticancer agents are discussed.
Subject(s)
Antineoplastic Agents/pharmacology , Basidiomycota/chemistry , Polyphenols/pharmacology , Topoisomerase Inhibitors/pharmacology , Animals , Antineoplastic Agents/chemistry , Cattle , Cell Cycle/drug effects , Cell Line, Tumor , Cell Proliferation/drug effects , Computers, Molecular , DNA Polymerase I/metabolism , DNA Polymerase beta/metabolism , DNA Topoisomerases, Type I/metabolism , Enzyme Activation/drug effects , HCT116 Cells , Humans , Inhibitory Concentration 50 , Models, Molecular , Molecular Weight , Polyphenols/chemistry , Rats , Topoisomerase Inhibitors/chemistryABSTRACT
Topoisomerase inhibitors are effective for antibacterial and anticancer therapy because they can lead to the accumulation of the intermediate DNA cleavage complex formed by the topoisomerase enzymes, which trigger cell death. Here we report the application of a novel enzyme-based high-throughput screening assay to identify natural product extracts that can lead to increased accumulation of the DNA cleavage complex formed by recombinant Yersinia pestis topoisomerase I as part of a larger effort to identify new antibacterial compounds. Further characterization and fractionation of the screening positives from the primary assay led to the discovery of a depside, anziaic acid, from the lichen Hypotrachyna sp. as an inhibitor for both Y. pestis and Escherichia coli topoisomerase I. In in vitro assays, anziaic acid exhibits antibacterial activity against Bacillus subtilis and a membrane permeable strain of E. coli. Anziaic acid was also found to act as an inhibitor of human topoisomerase II but had little effect on human topoisomerase I. This is the first report of a depside with activity as a topoisomerase poison inhibitor and demonstrates the potential of this class of natural products as a source for new antibacterial and anticancer compounds.
Subject(s)
Anti-Bacterial Agents/pharmacology , Ascomycota/chemistry , DNA Topoisomerases, Type I/metabolism , Depsides/pharmacology , Hydroxybenzoates/pharmacology , Topoisomerase Inhibitors/pharmacology , Anti-Bacterial Agents/isolation & purification , Anti-Bacterial Agents/toxicity , Biological Products/pharmacology , Cell Survival/drug effects , Depsides/isolation & purification , Depsides/toxicity , Detergents/pharmacology , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , Escherichia coli/drug effects , Escherichia coli/enzymology , High-Throughput Screening Assays , Humans , Hydroxybenzoates/isolation & purification , Hydroxybenzoates/toxicity , Magnesium/pharmacology , Small Molecule Libraries/pharmacology , Topoisomerase Inhibitors/isolation & purification , Topoisomerase Inhibitors/toxicity , Yersinia pestis/drug effects , Yersinia pestis/enzymologyABSTRACT
DNA topoisomerases are highly exploited targets for antimicrobial drugs. The spread of antibiotic resistance represents a significant threat to public health and necessitates the discovery of inhibitors that target topoisomerases in novel ways. However, the traditional assays for topoisomerase activity are not suitable for the high-throughput approaches necessary for drug discovery. In this study we validate a novel assay for screening topoisomerase inhibitors. A library of 960 compounds was screened against Escherichia coli DNA gyrase and archaeal Methanosarcina mazei DNA topoisomerase VI. Several novel inhibitors were identified for both enzymes, and subsequently characterised in vitro and in vivo. Inhibitors from the M. mazei topoisomerase VI screen were tested for their ability to inhibit Arabidopsis topoisomerase VI in planta. The data from this work present new options for antibiotic drug discovery and provide insight into the mechanism of topoisomerase VI.
Subject(s)
Archaeal Proteins/antagonists & inhibitors , Drug Evaluation, Preclinical/methods , Topoisomerase II Inhibitors , Topoisomerase Inhibitors/pharmacology , Anthraquinones/pharmacology , Arabidopsis/drug effects , Arabidopsis/enzymology , Arabidopsis/growth & development , DNA Topoisomerases, Type II , Drug Evaluation, Preclinical/instrumentation , Escherichia coli/enzymology , Hexylresorcinol/pharmacology , Methanosarcina/enzymology , Mitoxantrone/pharmacology , Quinacrine/pharmacology , Sulfolobus/enzymology , Suramin/pharmacologyABSTRACT
Pyrimidine compounds were identified as inhibitors of DNA topoisomerase IV through high-throughput screening. This study was designed to exemplify the in vitro activity of the pyrimidines against Gram-positive and Gram-negative microorganisms, to reveal the mode of action of these compounds and to demonstrate their in vivo efficacy. Frequencies of resistance to pyrimidines among Staphylococcus aureus and Streptococcus pneumoniae were <10(-10) at four times their minimum inhibitory concentrations (MICs). These compounds exhibited a dual mode of action through inhibition of the ParE subunit of DNA topoisomerase IV as well as the GyrB subunit of DNA gyrase, a homologue of DNA topoisomerase IV. Pyrimidines were shown to have MIC(90) values (MIC that inhibited 90% of the strains tested) of ≤2 mg/L against Gram-positive pathogens, including meticillin-resistant S. aureus, quinolone- and meticillin-resistant S. aureus, vancomycin-resistant enterococci, penicillin-non-susceptible S. pneumoniae and Streptococcus pyogenes, and MIC(90) values of 2- to >16 mg/L and ≤0.5 mg/L against the Gram-negative pathogens Haemophilus influenzae and Moraxella catarrhalis, respectively. The pyrimidines were bactericidal and exhibited a ca. 1000-fold reduction of the bacterial counts at 300 mg/kg in a S. pneumoniae lung infection model. The microbiological properties and in vivo efficacy of pyrimidines underscore their potential as candidates for the treatment of soft-tissue infections and hospital-acquired pneumonia.
Subject(s)
Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , DNA Topoisomerase IV/antagonists & inhibitors , Gram-Negative Bacteria/drug effects , Gram-Positive Cocci/drug effects , Pneumonia, Pneumococcal/drug therapy , Topoisomerase Inhibitors/pharmacology , Topoisomerase Inhibitors/therapeutic use , Animals , Anti-Bacterial Agents/chemistry , DNA Topoisomerase IV/chemistry , Disease Models, Animal , Female , Humans , Mice , Microbial Sensitivity Tests/standards , Models, Molecular , Pneumonia, Pneumococcal/microbiology , Streptococcus pneumoniae/drug effects , Topoisomerase II Inhibitors , Topoisomerase Inhibitors/chemistry , Treatment OutcomeABSTRACT
In this study, the inhibitory activities against DNA polymerases (pols) and DNA topoisomerases (topos) by eight major green tea catechin derivatives (flavan-3-ols) were investigated. Some catechins inhibited mammalian pols (α and ß) and human topos (I and II), with (-)-epigallocatechin gallate (EGCg) the strongest inhibitor of both enzyme types, showing IC(50) values of 3.8-21.5 and 2.0-20.0 µM, respectively. EGCg did not affect the activities of plant (cauliflower) pol α or prokaryotic pols and showed no effect on the activities of other DNA metabolic enzymes tested. Next, a method was established for assay of mouse one-cell zygote development inhibition, the catechin derivatives screened for bioactivity, and the inhibition was assessed and their effects ranked as: EGCg > GCg > Cg >> others. In the mouse one-cell zygote assay, EGCg at 50 µM increased abnormal cells and 75 µM of EGCg-induced apoptosis. The observed ranking of catechin derivative inhibition effects against mouse one-cell zygote development in vivo was similar to their ranking by topo inhibition in vitro rather than by pol inhibition; therefore, topo inhibition might have been effecting zygote development inhibition. These results suggested that catechin derivatives indeed reached the nuclear DNA where topo inhibition can occur, thus causing the observed cellular effects. From these findings, this zygote development inhibition assay will be useful as an anti-pregnant agent screening.
Subject(s)
Catechin/analogs & derivatives , Nucleic Acid Synthesis Inhibitors , Topoisomerase Inhibitors/pharmacology , Zygote/drug effects , Animals , Apoptosis , Catechin/chemistry , Catechin/pharmacology , Cattle , DNA/metabolism , DNA-Directed DNA Polymerase/metabolism , Humans , Mice , Rats , Tea/chemistry , Topoisomerase Inhibitors/chemistry , Zygote/cytology , Zygote/growth & developmentABSTRACT
DNA topoisomerases are nuclear enzymes that are the targets for several anticancer drugs. In this study we investigated the antiproliferative activity against human leukaemia cell lines and the effects on topoisomerase I and II of evodiamine, which is a quinazolinocarboline alkaloid isolated from the fruit of a traditional Chinese medicinal plant, Evodia rutaecarpa. We report here the anti-proliferative activity against human leukaemia cells K562, THP-1, CCRF-CEM and CCRF-CEM/C1 and the inhibitory mechanism on human topoisomerases I and II, important anti-cancer drugs targets, of evodiamine. Evodiamine failed to trap [Topo-DNA] complexes and induce any detectable DNA damage in cells, was unable to bind or intercalate DNA, and arrested cells in the G(2)/M phase. The results suggest evodiamine is a dual catalytic inhibitor of topoisomerases I and II, with IC(50) of 60.74 and 78.81 µM, respectively. The improved toxicity towards camptothecin resistant cells further supports its inhibitory mechanism which is different from camptothecin, and its therapeutic potential.